Get API key
Insider trading · Q3 2026 · CIK 1157601

Madrigal Pharmaceuticals, Inc. (MDGL) insider trading.

In Q3 2026, insiders at Madrigal Pharmaceuticals, Inc. reported 37 non-derivative transactions on 5 Forms 3, 4 and 5: 0 open-market purchases and 35 sales worth $7.9M.

Transactions
37
Purchases (P)
0
Sales (S)
35
Net shares, P minus S
-14,747
Insiders
3
Last filed
2026-09-11

Insiders

InsiderRelationshipTransactionsBuysSales
Sibold William JohnDirector, Officer · President and CEO35034
Kelley Shannon TOfficer · General Counsel101
Reed John CDirector100

Transactions

37 non-derivative rows, newest transaction first. Shares and prices as filed.
DateInsiderCodeSharesPriceOwned afterFiling
2026-09-11Sibold William JohnS (D)60$533.09202,907Form 4
2026-09-11Sibold William JohnS (D)218$535.94202,583Form 4
2026-09-11Sibold William JohnS (D)160$537.62202,423Form 4
2026-09-11Sibold William JohnS (D)687$540.59201,736Form 4
2026-09-11Sibold William JohnS (D)368$541.64201,368Form 4
2026-09-11Sibold William JohnS (D)1,202$542.6200,166Form 4
2026-09-11Sibold William JohnS (D)1,539$544.02198,627Form 4
2026-09-11Sibold William JohnS (D)761$544.83197,866Form 4
2026-09-11Sibold William JohnS (D)120$546.38197,746Form 4
2026-09-11Sibold William JohnS (D)106$534.06202,801Form 4
2026-09-09Sibold William JohnS (D)160$542.55202,967Form 4
2026-09-09Sibold William JohnS (D)131$527.88209,198Form 4
2026-09-09Sibold William JohnS (D)347$529.27208,851Form 4
2026-09-09Sibold William JohnS (D)522$530.23208,329Form 4
2026-09-09Sibold William JohnS (D)368$531.99207,961Form 4
2026-09-09Sibold William JohnS (D)512$533.09207,449Form 4
2026-09-09Sibold William JohnS (D)396$534.2207,053Form 4
2026-09-09Sibold William JohnS (D)644$535.27206,409Form 4
2026-09-09Sibold William JohnS (D)1,040$536.11205,369Form 4
2026-09-09Sibold William JohnS (D)640$537.17204,729Form 4
2026-09-09Sibold William JohnS (D)520$538.3204,209Form 4
2026-09-09Sibold William JohnS (D)215$539.03203,994Form 4
2026-09-09Sibold William JohnS (D)505$540.19203,489Form 4
2026-09-09Sibold William JohnS (D)362$541.65203,127Form 4
2026-08-17Kelley Shannon TS (D)664$514.9711,474Form 4
2026-08-15Reed John CA (A)647$0647Form 4
2026-07-20Sibold William JohnS (D)545$544.71211,034Form 4
2026-07-20Sibold William JohnS (D)280$555.05209,329Form 4
2026-07-20Sibold William JohnS (D)1$550.72209,609Form 4
2026-07-20Sibold William JohnS (D)153$550.01209,610Form 4
2026-07-20Sibold William JohnS (D)47$548.87209,763Form 4
2026-07-20Sibold William JohnS (D)680$547.7209,810Form 4
2026-07-20Sibold William JohnS (D)269$547.08210,490Form 4
2026-07-20Sibold William JohnS (D)275$545.71210,759Form 4
2026-07-20Sibold William JohnS (D)110$543.79211,579Form 4
2026-07-20Sibold William JohnS (D)140$542.75211,689Form 4
2026-07-17Sibold William JohnM (A)50,000—211,829Form 4

Transaction codes in this quarter

S: 35A: 1M: 1

Get MDGL insider transactions through the API

Request with your API key
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1157601&limit=100" \
  -H "Authorization: Bearer $SEC_API_KEY"

Insider trading API guide · MDGL company page · Madrigal Pharmaceuticals, Inc. on SEC.gov

Questions

Are insiders buying or selling Madrigal Pharmaceuticals, Inc. (MDGL)?

In Q3 2026, insiders at Madrigal Pharmaceuticals, Inc. reported 37 non-derivative transactions on 5 Forms 3, 4 and 5: 0 open-market purchases and 35 sales worth $7.9M. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.

Where do these Madrigal Pharmaceuticals, Inc. insider trades come from?

From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.

Source: SEC Insider Transactions Data Sets, Q3 2026, retrieved 2026-10-27. Footnotes, derivative holdings and amendments are in the linked filings. Not investment advice.

Plain-text version for agents and LLMs: /insider-trading/mdgl.md

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.